Evidence map›Paper›PMID 40482880›Full record

Observational studyThe Journal of pediatrics2025

Fidaxomicin Treatment of Clostridioides difficile Infections and Recurrences in Children and Adolescents: A Retrospective Multicenter Study.

Máire A Conrad, Abby L Kaplan, Sarah Weinbrom, Silvia Nastasio, Diana Jo, Katie Conover, Kathleen Lo, Enju Liu, Melissa Crawford, Sonia Michail and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Máire A ConradDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: conradm@chop.edu.
Abby L KaplanInflammatory Bowel Disease Center, Boston Children's Hospital, Boston, MA.
Sarah WeinbromDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA.
Silvia NastasioDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA.
Diana JoDepartment of Pediatrics, Inova Fairfax Hospital, Falls Church, VA; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's National Hospital, Washington, DC.
Katie ConoverDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Kathleen LoDivision of Pediatric Gastroenterology, Children's Hospital of Los Angeles, and Department of Pediatrics, Keck School of Medicine at the University of Southern California, Los Angeles, CA.
Enju LiuDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA; Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA.
Melissa CrawfordDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Sonia MichailDivision of Pediatric Gastroenterology, Children's Hospital of Los Angeles, and Department of Pediatrics, Keck School of Medicine at the University of Southern California, Los Angeles, CA.
Maribeth NicholsonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; Division of Pediatric Gastroenterology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Suchitra K HouriganNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Department of Pediatrics, Inova Fairfax Hospital, Falls Church, VA.
Judith R KelsenDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Stacy A KahnInflammatory Bowel Disease Center, Boston Children's Hospital, Boston, MA; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA.

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Identifying Genomic and Microbial Contributions in Early Childhood-Inflammatory Bowel DiseaseK23DK119585 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI CONRAD, MAIRE ABRAHAM · 2019 to 2023
$927k
Immune, Microbial, and Metabolic Factors that Impact Clostridioides difficile and Inflammatory Bowel Disease in ChildrenK23AI156132 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NICHOLSON, MARIBETH RUTH · 2021 to 2025
$876k
NIAID NIH HHS K23 AI156132NIDDK NIH HHS K23 DK119585NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

objectiveTo report the effectiveness and tolerability of treating children with primary and recurrent Clostridioides difficile infection (CDI) with fidaxomicin in a real-world, multicenter cohort. STUDY

designWe performed a multicenter, retrospective, observational study of fidaxomicin treatment for primary or recurrent CDI in children ages 12 months to 18 years old identified from 2013 to 2021 at 5 centers via electronic medical records. Outcomes included assessment of clinical response at day 14 after initiation of fidaxomicin treatment and clinical and microbiologic outcomes at day 60 after initiation of fidaxomicin treatment in the initial responders.

resultsOf the 95 patients included in this study, 84 (88.4%) were treated with fidaxomicin for a recurrent CDI, and 82 (86.3%) had at least one medical or surgical comorbidity. At the completion of fidaxomicin treatment (ie, by day 14 after initiation), 50 patients (52.6%) had a clinical cure and an additional 29 (30.5%) had improvement of symptoms. Among 79 patients who responded to fidaxomicin treatment, 17 (21.5%) had a clinical and microbiologically confirmed recurrence of CDI by day 60, likely representing relapse. Patients with inflammatory bowel disease were less likely to achieve clinical cure at day 14 (OR 0.27 (95% CI 0.11, 0.70)), but 20 patients with inflammatory bowel disease who had initial clinical cure or response did not have a demonstrable increased risk of recurrence at day 60. The most common adverse events reported during therapy were abdominal pain and nausea.

conclusionsIn this retrospective, real-world study, fidaxomicin for children with CDI appears to be well tolerated and is associated with low rates of treatment failure.

Indexed as

Anti-Bacterial AgentsClostridium InfectionsFidaxomicinAdolescentChildChild, PreschoolClostridioides difficileFemaleHumansInfantMaleRecurrenceRetrospective StudiesTreatment OutcomeAnti-Bacterial AgentsFidaxomicinchildrencolitisdysbiosisfecal microbiota transplantation

Identifiers

PMID40482880
PMCPMC12459756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.